Scilex Holding (SCLX) Enterprise Value Growth (3y) (2023 - 2026)
Scilex Holding (SCLX) Enterprise Value Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -208.63% |
| Dec 31, 2025 | -90.62% |
| Sep 30, 2025 | -274.85% |
| Jun 30, 2025 | 69.32% |
| Mar 31, 2025 | 65.45% |
| Dec 31, 2024 | 71.66% |
| Sep 30, 2024 | 12.68% |
| Jun 30, 2024 | -199.02% |
| Mar 31, 2024 | -79.39% |
| Dec 31, 2023 | -404.64% |